@misc{Bochenek_Tomasz_The_2010,
 author={Bochenek, Tomasz},
 address={Kraków},
 howpublished={online},
 year={2010},
 school={Wydział Lekarski},
 language={pol},
 abstract={OBJECTIVE: The currently recommended standard treatment of venous thromboembolism (VTE) are oral anticoagulants (OA) in majority of patients and low-molecular-weight heparins (LMWH) in selected subpopulations. The titration of OA doses is difficult and often ineffective. The goal of this research was to compare LMWH and OA in VTE treatment, in terms of effectiveness, safety and cost-effectiveness. METHODS: The systematic review of scientific literature and the metaanalysis of reported treatment outcomes were performed. The cost analysis and the cost-effectiveness analysis were performed. The data on costs of treatment were collected through the retrospective review of patient records obtained from three hospitals and anticoagulation clinic, pharmaceutical reimbursement databases and public payer’s charge tariffs for medical services. The modeling (decision tree) was performed. RESULTS: The most important differences between LMWH and OA, in favor of LMWH, were related to better prevention of VTE incidence and better prevention of small bleedings. With respect to none of assessed outcomes OA were better than LMWH. Within a six month treatment period the ICER ratio of avoiding the complication incidents was 49.865 zlotys (12.242 EURO) from payer perspective and 3.609 zlotys (887 EUR) from patient perspective. CONCLUSION: LMWH offer better effectiveness and safety than OA but the t},
 abstract={reatment is associated with considerably higher costs. Medical considerations support more general use of LMWH in VTE treatment but the economic constraints are essential barrier in dissemination of this method of treatment.},
 title={The analysis of effectiveness and costs of using low-molecular-weight heparins in comparison with oral anticoagulants for the treatment of venous thromboembolism},
 type={Praca doktorska},
 keywords={cost-effectiveness analysis, venous thromboembolism, deep vein thrombosis, pulmonary embolism},
}